Company: ANIX
Filing Date: 2025-01-10
Form Type: S-8
Source: 0001493152-25-001798
Chunk: 46

Company: Anixa Biosciences Inc
Filing Date: 2025-01-10
Form: S-8
Chunk 46
---
 resale and the position, office or other material relationship which a Selling Stockholder has had within the past three years with the Company or any of its predecessors or affiliates.

| 28 |

<div align='center'>USE OF PROCEEDS</div>

We will not receive any proceeds from the resale of our Common Stock by the Selling Stockholders pursuant to this prospectus. However, we will receive the exercise price of any Common Stock issued to the Selling Stockholders upon cash exercise by them of their options. We would expect to use these proceeds, if any, for general working capital purposes. We have agreed to pay the expenses of registration of these shares.

<div align='center'>PLAN OF DISTRIBUTION</div>

In this section of the prospectus, the term “Selling Stockholder” means and includes:

| ● | the                                                                                                                               
 persons identified in the table above as the Selling Stockholders;                                                                |
| ● | those                                                                                                                             
 persons whose identities are not known as of the date hereof but may in the future be eligible to receive options under the 2018  
 Plan or be eligible to purchase shares under the ESPP; and                                                                        |
| ● | any                                                                                                                               
 of the donees, pledgees, distributees, transferees or other successors in interest of those persons referenced above who may: (a) 
 receive any of the shares of our common stock offered hereby after the date of this prospectus and (b) offer or sell those shares 
 hereunder.                                                                                                                        |

The shares of our Common Stock offered by this prospectus may be sold from time to time directly by the Selling Stockholders. Alternatively, the Selling Stockholders may from time to time offer such shares through underwriters, brokers, dealers, agents or other intermediaries. The Selling Stockholders as of the date of this prospectus have advised us that there were no underwriting or distribution arrangements entered into with respect to the Common Stock offered hereby. The distribution of the Common Stock by the Selling Stockholders may be effected: in one or more transactions that may take place on The NASDAQ Capital Market (including one or more block transaction) through customary brokerage channels, either through brokers acting as agents for the Selling Stockholders, or through market makers, dealers or underwriters acting as principals who may resell these shares on The NASDAQ Capital Market; in privately-negotiated sales; by a combination of such methods; or by other means. These transactions may be effected at market prices prevailing at the time of sale, at prices related to